Cantor Fitzgerald Comments on ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued on Tuesday, February 25th. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnology company will post earnings of ($2.72) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $200.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64.

ASND has been the topic of several other reports. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price on the stock. Evercore ISI upped their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. TD Cowen decreased their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $202.36.

Ascendis Pharma A/S Trading Up 0.7 %

Shares of ASND opened at $152.61 on Thursday. The company’s 50 day simple moving average is $135.40 and its 200-day simple moving average is $133.67. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $158.06. The firm has a market cap of $9.26 billion, a PE ratio of -21.49 and a beta of 0.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. T. Rowe Price Investment Management Inc. increased its stake in shares of Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock worth $375,226,000 after purchasing an additional 960,504 shares in the last quarter. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after buying an additional 753,859 shares during the last quarter. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $60,000. RA Capital Management L.P. boosted its position in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock worth $1,392,221,000 after acquiring an additional 402,316 shares during the last quarter. Finally, Vestal Point Capital LP grew its stake in Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock worth $71,588,000 after acquiring an additional 270,000 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.